Provider review
Believe Health Review: The Third Copy of the Same Peptide Storefront
Believe Health sells nineteen peptide programs. So does Alinwell. So does Longevixx. Read card by card on 1 September 2026, the three menus carry the same nineteen names, the same descriptions word for word and the same heading — and eighteen of the nineteen prices match to the dollar across all three. The one that does not is BPC-157, which Believe sells at $210 against $250 elsewhere. What separates the three is not the products. It is that one of them publishes lab results and this is not that one.
The cheapest BPC-157 of three identical storefronts, sold from a Wyoming mailbox by a company that publishes no lab result, names no pharmacy and will not print its GLP-1 price.
Worth trusting if
- You are buying BPC-157 and price is the only axis you are comparing on
- You want the peptide prices visible before any questionnaire, which they are
- You want tesamorelin or PT-141, the two molecules here with completed phase 3 trials
Be skeptical if
- You want to read a certificate of analysis, because this site publishes none
- You want to know who compounds your prescription, which it never says
- You are also shopping its GLP-1 line, whose price it does not publish at all
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens believe.health. A link is not a recommendation to take anything.
Provenance
What Believe Health actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- BPC-157 — $210/mo, against $250 on the two sites selling the identical card. Five further products here contain the molecule, from $199 to $379.
- GHK-Cu — $249/mo. The same sentence appears on two blends that are mostly other peptides.
- NAD+ Injection — $199/mo, the cheapest program on the menu and the same figure the other two storefronts charge.
- Sermorelin — $249/mo.
- Tesamorelin — $299/mo alone, or $349 paired with ipamorelin — a pairing that carries this same sentence and never describes ipamorelin.
- MOTS-C — $279/mo.
- Epithalon — $249/mo alone, or $319 paired with GHK-Cu, where the pair carries this sentence.
- Thymosin A-1 — $299/mo, the only product in the immune category.
- DSIP — $249/mo. A three-peptide blend at $329 carries this same sentence.
- Semax / Selank — $299/mo, sold as a pair rather than separately.
- PT-141 — $249/mo, the only product in the sexual-health category.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
6
Molecules with human evidence
For the use they are sold for, out of 11 products reviewed here. The evidence belongs to the molecule, not to Believe Health.
8
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Believe Health’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
BPC-157BPC-157 · Compounded (503A)No trial supports this claim
“Body Protection Compound — used to support tissue repair, gut health, and recovery.”
Read on the Believe Health site, September 2026
Phase 1 only
What the trials show for BPC-157
- NCT02637284 — Phase 1, unknown status, n=42. The registry record for BPC-157 in humans sits at phase 1 — tolerability, not effect — and its status is unknown rather than completed.
This is the one product Believe prices differently from the two identical storefronts beside it, and the discount does not change what is behind it. A phase 1 record establishes whether a dose is tolerated; it measures neither tissue repair, nor gut symptoms, nor recovery, which is the whole of the sentence. The registry does not record the study as completed — its status is unknown.1
GHK-CuGHK-Cu · Compounded (503A)Claim reaches past the trials
“A copper peptide used to support skin, collagen, hair, and tissue regeneration.”
Read on the Believe Health site, September 2026
Phase 2 only
What the trials show for GHK-Cu
- NCT07437586 — Phase 2, recruiting, n=60. Acute skin wound healing, recruiting. The completed GHK-Cu registry record is a 27-participant study of facial skin quality; neither studies hair.
Three of the four nouns have a thin literature behind them and one has none. Skin, collagen and tissue are what GHK-Cu research is about. Hair appears in no GHK-Cu record in the registry in any formulation — and Believe files this product under a heading reading "Skin · Hair · Longevity", which puts the untested word in the category name as well as the sentence.2
NAD+ InjectionNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“A cellular coenzyme used to support energy, mental clarity, and healthy aging.”
Read on the Believe Health site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
Energy, mental clarity and healthy aging are exactly what an injected NAD+ trial would have to measure, and none has reported. The literature offered in support is about oral precursors — different molecules, different route — and results do not transfer between the two any more than oral iron transfers to an infusion.3
SermorelinSermorelin · Compounded (503A)Claim reaches past the trials
“A growth-hormone-releasing hormone used to support natural GH production, recovery, and sleep.”
Read on the Believe Health site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests recovery or sleep quality as an outcome in healthy adults. A parallel ClinicalTrials.gov search for sermorelin as an intervention returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
One of the three promises is the best-supported claim on this menu and the other two were never an outcome in any trial. Sermorelin does raise growth hormone — that is what all 19 randomized trials measured, and the newest of them is from 2005. Recovery and sleep are not in that literature, and nothing on the card separates the tested third from the rest.4
TesamorelinTesamorelin · Compounded (503A)Claim reaches past the trials
“A growth-hormone-releasing analog used to support fat metabolism and healthy body composition.”
Read on the Believe Health site, September 2026
Phase 3 trials
What the trials show for Tesamorelin
- NCT00123253 — Phase 3, completed, n=412. The pivotal trial of tesamorelin in HIV patients with excess abdominal fat. The outcome measured was visceral abdominal fat, in that population.
- NCT00608023 — Phase 3, completed, n=263. The extension study in the same HIV-associated lipodystrophy population.
The strongest trial record on the menu, earned in a population this site is not addressing. Both phase 3 trials studied HIV-associated lipodystrophy and measured visceral abdominal fat in those patients. "Healthy body composition" in a general adult is an extrapolation the card makes without marking it.5,6
MOTS-CMOTS-c · Compounded (503A)No trial supports this claim
“A mitochondrial-derived peptide used to support cellular energy, metabolism, and exercise capacity.”
Read on the Believe Health site, September 2026
Phase 2 only
- NCT07505745 MOTS-MET — Phase 2, recruiting, n=120. Recruiting, not reporting. No completed human efficacy result exists for a metabolic outcome.
The right trial is running and has not reported. MOTS-MET is recruiting 120 participants for a metabolic outcome; until it finishes there is nothing behind a claim about energy, metabolism or exercise capacity. An unfinished literature is not a hostile one — it is simply not yet support.7
EpithalonEpithalon (epitalon) · Compounded (503A)No trial supports this claim
“A peptide studied for supporting cellular longevity, sleep quality, and healthy aging.”
Read on the Believe Health site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search returned zero studies for "Epithalon", zero for the spelling "Epitalon" and zero for "Epithalamin" — no registered trial of this molecule exists anywhere in the registry, for any indication, under any spelling. In PubMed, a search restricted to the randomized-controlled-trial publication type returns zero records. The randomized literature a looser search surfaces tests EPITHALAMIN, a peptide extract of bovine pineal gland rather than the synthetic tetrapeptide, and comes from a single research group.
"Studied for" is carrying the sentence. Epithalon has no registered trial anywhere in the world under any of its three spellings and no randomized-controlled-trial record in PubMed. The work usually cited concerns epithalamin, a bovine pineal extract — a different substance, not an earlier form of this one.8
Thymosin A-1Thymosin alpha-1 · Compounded (503A)Claim reaches past the trials
“An immune-modulating peptide used to support immune resilience and balance.”
Read on the Believe Health site, September 2026
Phase 3 trials
- NCT02867267 TESTS — Phase 3, completed, n=1,106. Thymosin alpha-1 in SEPSIS — completed phase 3, 1,106 critically ill patients. The strongest evidence the molecule has, in a population nobody joins by choice.
Searched live on 2026-09-01, this molecule has 64 randomized-trial records and 64 registered studies — and reading them rather than counting them, they are hepatitis B, sepsis, severe pancreatitis, cirrhosis and cancer immunotherapy. Modulating immunity in a critically ill patient is a real, well-tested effect. "Immune resilience and balance" in a well adult is a different claim, and it has not been tested.9
DSIPDSIP (delta sleep-inducing peptide) · Compounded (503A)Claim reaches past the trials
“Delta sleep-inducing peptide used to support deep, restorative sleep.”
Read on the Believe Health site, September 2026
No trial for this use
Searched live on 2026-09-01. The same searches were run for tirzepatide in the same pass to confirm they were working, and returned 2,451 PubMed records, 134 randomized-trial records and 278 registry studies. DSIP returns 544 PubMed records, 7 carrying the randomized-controlled-trial publication type, and ZERO registry studies — the single registry hit is an L-carnitine study that does not involve DSIP. Reading the 7 rather than counting them: two are false positives, including a cervical-spine screw-fixation trial where DSIP is an unrelated abbreviation. The genuine sleep trials are two, published in 1981 and 1992, both in patients with chronic insomnia.
There is human sleep evidence here, and it is 34 years old and about someone else. Two randomized trials tested DSIP in people with chronic insomnia, in 1981 and 1992. No registered trial of the molecule exists today, and nothing has tested deep or restorative sleep in adults who already sleep normally.10
Semax / SelankSemax and Selank · Compounded (503A)No trial supports this claim
“Nootropic peptides used to support focus, mood, and cognitive resilience.”
Read on the Believe Health site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search returns zero records naming Semax and zero naming Selank. The published literature is not empty and the distinction matters: PubMed holds 207 records mentioning Semax, of which one carries the randomized-controlled-trial publication type — a 2007 Russian-language paper on motor neuron disease, not attention or cognition. It holds 68 mentioning Selank, of which two are randomized trials, both in the same Russian journal and both in anxiety disorders.
Three randomized trials exist across both molecules and none is about focus or cognition in a healthy person. Semax's single record is in motor neuron disease; Selank's two are in anxiety disorders. Neither molecule has a registered trial anywhere, and "nootropic" is a shelf label rather than a finding.11
PT-141Bremelanotide (PT-141) · Compounded (503A)Claim reaches past the trials
“A peptide used to support libido and sexual arousal in men and women.”
Read on the Believe Health site, September 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Premenopausal women with hypoactive sexual desire disorder. One of the two trials behind the FDA approval of bremelanotide.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The identical second trial, in the same population.
Half the sentence rests on 1,437 participants and half rests on nobody. RECONNECT 1 and 2 enrolled premenopausal WOMEN with hypoactive sexual desire disorder, and they are the reason an approved product exists. The men's half was not tested in that record, and Believe never mentions the approved version of the molecule at all.12
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named anywhere, and the census is dated rather than impressionistic: on 2026-09-01 the visible text and DOM of ten pages plus both production bundles were searched, returning zero occurrences of "503A", "503B" and "". Every pharmacy reference is class-level — "partner compounding pharmacies", "state-licensed compounding pharmacies", and a "COMPOUNDED IN USA" badge on the peptides page. No laboratory, prescriber or medical group is named either. Its terms then ask the buyer to waive the right to fill a prescription at a pharmacy of their choice, which is a waiver in favor of a party the site never identifies, and disclose that prescriptions may ship without child-resistant packaging.
Read on the Believe Health site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
Nothing is published. A census of the peptides page on 2026-09-01 returned zero occurrences of "certificate of analysis" or "COA" in the visible text, and no potency, purity or sterility result appears anywhere on the site. The page carries a "COMPOUNDED IN USA" badge, which is a statement about geography rather than about testing. What makes the absence measurable rather than merely typical is the comparison: the identical menu at Alinwell links seventeen certificates naming both the laboratory and the compounding pharmacy. Three storefronts, one of them showing its work.
Read on the Believe Health site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Believe Health makes four different statements about its footprint and publishes no list. Its homepage badges "50-STATE CARE" and a counter reading "50 STATES COVERED"; its about page says "50 STATES SERVED". Its own FAQ answers the question circularly — "Believe Health operates via telehealth across the states where we operate." No exclusion list appears anywhere, and the intake's state selector is the only enumerable set at 51 entries.
Read the full licensing claim
"Reviewed by a licensed provider" and "Compounded in a U.S. pharmacy" on each of the nineteen peptide cards, plus a site-wide disclaimer referring to "state-licensed compounding pharmacies". No license number, prescriber or medical group is published anywhere.
Read on the Believe Health site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- The nineteen peptide prices are visible on a public page before any questionnaire, account or email — unlike its GLP-1 line, which publishes no price at all.
- Its BPC-157 is the cheapest of the three identical storefronts, at $210 against $250.
- Its disclaimer states plainly that compounded medications are not FDA-approved and that their safety, efficacy and quality have not been independently verified by the FDA.
Show 4 more
- It makes no testing claim it cannot support. Several sellers assert third-party testing with nothing behind it; Believe asserts none, which is at least consistent.
- Every card states that a licensed provider reviews the request, so nothing is offered as available without a prescription.
- Tesamorelin and PT-141 are real molecules with completed phase 3 trials behind them.
- No FDA warning letter for the company.
- No certificate of analysis exists anywhere on the site — no potency, purity or sterility result for any of the nineteen products.
- No pharmacy, laboratory, prescriber or medical group is named. A census across ten pages and both bundles returned zero hits for 503A, 503B.
- It publishes no GLP-1 price at all while promising "flat-rate pricing and no hidden fees" and "the price we quote is the price you pay, period" on every treatment page.
Show 7 more
- Its terms ask you to waive the right to fill your prescription at a pharmacy of your choice, in favor of a company the site does not name.
- Three cancellation notice periods are live at once: 48 hours in the terms, 30 days in the treatment-page FAQ, and "cancel anytime" at checkout.
- Its terms disclose that prescriptions may ship without child-resistant packaging, and impose a $35 disposal fee on returned medication the same policy says cannot be returned.
- Eight of nineteen cards carry a description belonging to one ingredient, and one of them files a copper peptide under a heading that promises hair.
- Nine of the eleven molecules we graded claim more than their trials show; three have no registered trial anywhere in the world.
- The only address published is a mailbox number in Casper, Wyoming, on a site whose contact page says "telehealth only".
- Its own FAQ answers "where do you operate?" with "across the states where we operate", beside a homepage counter claiming 50.
Verdict
The bottom line
The products are not the question here, because they are the same nineteen products the two sites next door sell, described in the same words. The question is what each company will let you verify, and this one will let you verify nothing: no certificate, no pharmacy, no laboratory, no prescriber, and no price at all on the GLP-1 half of its catalog. If you want this menu, one of the three storefronts publishes seventeen lab reports. Buy from that one.
Opens believe.health. A link is not a recommendation to take anything.
Three storefronts, one shop
On 1 September 2026 we read three peptide pages with the same tool and compared them card by card.
| | Alinwell LLC | Longevixx LLC | Believe Health LLC | |---|---|---|---| | Registered | Southlake, TX | Charlotte, NC | Casper, WY | | Programs | 19 | 19 | 19 | | Descriptions | identical | identical | identical | | Prices matching | — | 19/19 with Alinwell | 18/19 | | Certificates of analysis | 17 published | none | none | | Pharmacy named | in the certificates | no | no |
The single price that differs across all three is BPC-157: $210 here, $250 at the other two.
Three separate limited companies in three states, none of which mentions the others anywhere. That points to a shared vendor or platform. It is not evidence of common ownership and we are not claiming any.
What it does is remove every variable except one. When the products, the prices and the sentences are constants, the only thing left to compare is what each company will let a buyer check — and on that axis Believe Health publishes nothing at all.
The site-wide disclaimer is the same paragraph as Longevixx's, word for word, down to "The platform does not practice medicine, write prescriptions, or dispense pharmaceuticals."
Full analysis — 5 more sectionsWhat it will not tell you · The half of the catalog with no price · The descriptions belong to the wrong products · What the trials show · What this means if you are buying
What it will not tell you
No pharmacy. No laboratory. No prescriber. No medical group.. No compounding class — a census over ten pages and both production bundles returned zero occurrences of "503A", "503B" and "".
The peptides page carries a badge reading "COMPOUNDED IN USA". That is a statement about geography.
Its terms then go further than silence. Buying the service waives your right to have the prescription filled at a pharmacy of your choice — a waiver in favor of a company the site never identifies. The same terms disclose that prescriptions may ship without child-resistant packaging, and impose a $35 disposal fee on returned medication that the same policy says cannot be returned.
The half of the catalog with no price
Believe Health sells GLP-1s too, and publishes no rate for any of them.
Every treatment page promises "flat-rate pricing and no hidden fees" and "The price we quote is the price you pay, period." No price is quoted. The figures exist in shipped code and render on no page a reader can reach.
That is why the sibling cost site declined this company and why this one does not have to: the peptide prices are public, so the peptide line can be reviewed on its own terms. The unpriced GLP-1 line is a finding, not a gap in our reading.
The descriptions belong to the wrong products
Eight of nineteen programs are blends, and every blend inherits a description from one ingredient.
| Program | The sentence under it | Whose it is | |---|---|---| | BPC-157 / GHK-Cu / KPV / TB500 — $379 | "A copper peptide used to support skin, collagen, hair…" | GHK-Cu's | | BPC-157 / TB-500 / GHK-Cu — $349 | the same copper-peptide sentence | GHK-Cu's | | GHK-Cu / Epithalon — $319 | "A peptide studied for supporting cellular longevity…" | Epithalon's | | Tesamorelin / Ipamorelin — $349 | "A growth-hormone-releasing analog…" | Tesamorelin's | | BPC-157 / TB500 — $299 | "Body Protection Compound…" | BPC-157's | | BPC-157 / KPV / TB500 — $329 | the same BPC-157 sentence | BPC-157's | | BPC-157 Acetate — $199 | the same BPC-157 sentence | BPC-157's | | DSIP / BPC / CJC — $329 | "Delta sleep-inducing peptide…" | DSIP's |
Ipamorelin is never described anywhere on the site. Neither is KPV.
There is one addition here the other two do not have. Believe files GHK-Cu under a category heading reading "Skin · Hair · Longevity" — so the word with no evidence behind it appears in the section name as well as in the sentence.
What the trials show
Of the eleven molecules graded, two have completed phase 3 trials, two have a trial still recruiting, one sits at phase 1, and four have no registered trial anywhere.
Tesamorelin — 675 participants across two completed phase 3 trials, studying visceral fat in HIV-associated lipodystrophy. 5
PT-141 — 1,437 premenopausal women with hypoactive sexual desire disorder, the basis of an FDA approval. 12 Sold here "in men and women".
Thymosin alpha-1 — 64 randomized trials and 64 registered studies, all in hepatitis, sepsis, pancreatitis, cirrhosis or oncology. 9
Sermorelin — 19 randomized trials, newest from 2005, all measuring growth hormone secretion or growth in children. 4
Epithalon — no registered trial anywhere under any of three spellings. 8
DSIP — zero registered studies; two genuine sleep trials, from 1981 and 1992, both in chronic insomnia. 10
BPC-157, the product Believe prices below its two siblings, sits at phase 1 with a registry status of "unknown". 1
What this means if you are buying
The evidence problems belong to the molecules and follow you to any seller. The problem that belongs to this seller is that there is nothing here to check: no lab report, no named pharmacy, no named prescriber, and a waiver signing away your choice of where the prescription goes.
One of the three identical storefronts publishes seventeen certificates. If this menu is what you want, that is the one to buy it from — and the $250 BPC-157 there costs $210 more than the one here, which is the price of being able to read a lab result.
Questions
Frequently asked questions
Is Believe Health the same company as Alinwell or Longevixx?
Not on any evidence any of them publishes. They are three separate limited companies registered in Texas, North Carolina and Wyoming, and none mentions the others. What is true is that all three sell the same nineteen peptide programs with the same descriptions and, in eighteen of nineteen cases, the same prices — which points to a shared vendor or platform rather than to common ownership.
Does Believe Health publish test results?
No. A census of its peptides page on 1 September 2026 found zero occurrences of "certificate of analysis" or "COA", and no potency, purity or sterility result appears anywhere on the site. Its "COMPOUNDED IN USA" badge is a statement about where, not about what was tested.
Why is its BPC-157 cheaper?
Believe sells it at $210 a month against $250 on the two identical storefronts. Nothing on the site explains the difference, and it does not change the evidence: the human registry record for BPC-157 is a single phase 1 study whose status is listed as unknown.
What does its GLP-1 treatment cost?
Believe Health does not say. Every treatment page promises "flat-rate pricing" and "the price we quote is the price you pay, period", and no GLP-1 rate is published anywhere on the site. That is the reason our sibling cost site does not carry this company at all.
Which pharmacy fills the prescription?
It never says, and its terms ask you to waive the right to choose one. The site refers only to "partner compounding pharmacies" and "state-licensed compounding pharmacies", names none of them, and never uses the words 503A or 503B anywhere.
Glossary
Key terms
Show definitions
- Certificate of analysis
- A laboratory report for one manufactured lot, giving identity, potency and sterility results against a specification. Believe Health publishes none.
- Pharmacy-choice waiver
- A term in which a buyer gives up the right to have a prescription dispensed at a pharmacy they select. Believe Health's terms contain one, without naming the pharmacy it operates in favor of.
Compare
Others selling what Believe Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Believe Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 12 sources
- US National Library of Medicine (2026). BPC-157 — registry record, phase 1, status unknown, NCT02637284. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02637284
- US National Library of Medicine (2026). GHK-Cu — registry record, phase 2, recruiting, acute skin wound healing, NCT07437586; the completed GHK-Cu record is a 27-participant study of facial skin quality, and no registry record studies hair. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07437586
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; and ClinicalTrials.gov search: intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England Journal of Medicine 357(23):2359-70. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Theratechnologies (2026). TH9507 in Patients With HIV-Associated Lipodystrophy, NCT00123253 — phase 3, completed, enrolment 412; and TH9507 Extension Study, NCT00608023 — phase 3, completed, enrolment 263. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT00123253
- US National Library of Medicine (2026). MOTS-MET — MOTS-c registry record, phase 2, recruiting, NCT07505745. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07505745
- US National Library of Medicine (2026). ClinicalTrials.gov intervention search: "Epithalon", "Epitalon" and "Epithalamin" — zero studies under any spelling; PubMed restricted to randomized controlled trial[pt] — zero records. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=Epithalon
- US National Library of Medicine (2026). TESTS — The Efficacy and Safety of Ta1 for Sepsis, NCT02867267, phase 3, completed, enrolment 1,106. Intervention search "thymalfasin OR thymosin alpha-1" returned 64 studies, in hepatitis, sepsis, pancreatitis, cirrhosis and oncology. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02867267
- US National Library of Medicine (2026). PubMed search: (delta sleep-inducing peptide OR DSIP) AND randomized controlled trial[pt] — 7 records, two of them false positives, the two genuine sleep trials published 1981 and 1992 in chronic insomnia; ClinicalTrials.gov intervention search — zero DSIP studies. The same searches run for tirzepatide in the same pass returned 134 randomized-trial records and 278 registry studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=%28delta+sleep-inducing+peptide+OR+DSIP%29+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov intervention search: zero records naming Semax and zero naming Selank. PubMed: 207 records mentioning Semax, one carrying the randomized-controlled-trial publication type (2007, motor neuron disease); 68 mentioning Selank, two randomized trials, both in anxiety disorders. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=Semax
- Kingsberg SA, Clayton AH, Portman D, Williams LA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology 134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.